FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca manufacturing investment in Maryland
24 November
2025
AstraZeneca plans $2 billion manufacturing investment in Maryland,
supporting 2,600 jobs and catalysing economic growth
New capacity at AstraZeneca's Frederick and Gaithersburg facilities
will accelerate production of cancer, rare and chronic disease
medicines
Fourth major US manufacturing investment announced this year,
advancing AstraZeneca's historic $50 billion commitment to
medicines manufacturing and R&D
AstraZeneca today announces plans to invest $2 billion to expand
its long-standing manufacturing footprint in Maryland. This
includes a significant expansion of its flagship biologics
manufacturing facility in Frederick and construction of a new
state-of-the-art facility in Gaithersburg for the development
and clinical supply of innovative molecules to be used in
clinical trials. The investment will support 2,600 jobs across the
two sites in the state including the retention of local roles,
construction activity, and the creation of 300 highly skilled
jobs.
The Frederick facility currently produces biologics, a type of
medication used across AstraZeneca's portfolio of cancer, auto
immune, respiratory and rare disease treatments. The planned
expansion will nearly double commercial manufacturing capacity,
enabling increased supply of existing medicines and, for the first
time, production across the Company's rare disease portfolio.
It will create 200 highly skilled jobs and 900 construction roles
and is expected to be operational in 2029.
In parallel, AstraZeneca will build a new clinical manufacturing
facility to expand its footprint in Gaithersburg. The
facility, which will be fully operational by 2029, will create an
additional 100 jobs, retain 400 roles and support a further 1,000
construction-related jobs.
Both the expanded facility in Frederick and the new facility in
Gaithersburg will leverage cutting-edge AI, automation and data
analytics and be built to the highest environmental
standards.
Maryland Governor, Wes Moore, said: "AstraZeneca's commitment to Maryland speaks to
our unique, world-class biotech ecosystem. This landmark
investment affirms our reputation as a global leader in life
sciences, while strengthening the U.S. medicine supply chain,
accelerating the development of life-saving therapies, and creating
hundreds of jobs. We are proud to partner with AstraZeneca to grow
our economy and build new pathways to work, wages, and wealth for
all."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today
marks a landmark moment for Maryland and American patients. As the
state's largest biopharmaceutical employer, we are deepening our
long-standing commitment to Maryland - supporting 2,600 jobs,
catalysing economic growth and bringing our extensive rare disease
portfolio onshore for the first time. This investment strengthens
the resilience of the US medicines supply chain and accelerates
access to transformative therapies for patients across America and
around the world."
Today's announcement is part of AstraZeneca's historic $50 billion
investment announced in July and follows a series of US commitments
over the past six months, including unveiling a new cell therapy
manufacturing facility in Rockville, Maryland, a new drug substance
manufacturing facility in Virginia and the expansion of the
Company's existing manufacturing facility in Coppell,
Texas.
The US is AstraZeneca's largest market by sales and is also home to
19 R&D, manufacturing and commercial sites. The Company's US
workforce exceeds more than 25,000 people and supports more than
100,000 jobs overall across the country. In 2025, AstraZeneca
created approximately $20 billion of overall value to the American
economy.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 24 November 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
